In addition, other immune checkpoint proteins were also inversely associated with increases in TyG.<h4>Conclusion</h4>We discovered that low plasma levels of BTLA and LAG-3 before HCV therapy significantly correlate with an increased risk of developing metabolic disorders after treatment. Here, BTLA is linked to metabolic disease.